Showing results (431-440 of 6,499) with videos related to
Sort By:
Pageof 650
Cancer Immunology, Immunotherapy : CII|November 30, 2019
The promise and peril of targeting cell metabolism for cancer therapyJonathan M WeissCancer Immunology, Immunotherapy : CII|November 14, 2019
Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1Tyler R McCaw, Mei Li, Dmytro Starenki, et al.Cancer Immunology, Immunotherapy : CII|December 8, 2017
Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screeningXu-Chao Zhang, Xu Cao, Chun Sun, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1989
Cell-mediated immunity is enhanced by cytostatic drugs continuously released at the site of antigenic stimulationA M Claessen, H Valster, H Bril, et al.Cancer Immunology, Immunotherapy : CII|December 6, 2017
Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndromeLarisa J Geskin, Oleg E Akilov, Soonyou Kwon, et al.Cancer Immunology, Immunotherapy : CII|December 6, 2017
The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastasesYun Wang, Hao-Cheng Lin, Ma-Yan Huang, et al.Cancer Immunology, Immunotherapy : CII|November 17, 2017
Cancer vaccine strategies: translation from mice to human clinical trialsJay A Berzofsky, Masaki Terabe, Jane B Trepel, et al.Cancer Immunology, Immunotherapy : CII|January 24, 2019
A potential role for peripheral natural killer cell activity induced by preoperative chemotherapy in breast cancer patientsRyungsa Kim, Ami Kawai, Megumi Wakisaka, et al.Cancer Immunology, Immunotherapy : CII|December 20, 2019
Elevated GALNT10 expression identifies immunosuppressive microenvironment and dismal prognosis of patients with high grade serous ovarian cancerGuodong Zhang, Jiaqi Lu, Moran Yang, et al.Cancer Immunology, Immunotherapy : CII|February 14, 2019
Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimusInge M Werter, Charlotte M Huijts, Sinéad M Lougheed, et al.Pageof 650